文献速递肝病

将非酒精性脂肪性肝病纳入代谢综合征定义中的预后价值

The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-29

本研究基于1999至2018年美国国家健康与营养调查(NHANES)数据,比较传统代谢综合征(MetS)定义与纳入非酒精性脂肪性肝病(NAFLD)的新型诊断标准(MetS2)在识别代谢紊乱个体及预测不良结局方面的准确性。共纳入46184人,32.54%符合MetS标准,40.54%符合MetS2标准,后者额外纳入8.00%(n=3694)个体。MetS与MetS2均与全因死亡、心血管疾病死亡及主要不良心血管事件显著相关。

要点

  • 在46184名NHANES参与者中,32.54%符合MetS标准,40.54%符合MetS2标准,后者额外识别8.00%个体。
  • MetS与全因死亡(HR 1.184,95%CI 1.110-1.263,p<0.001)和心血管疾病死亡(SHR 1.288,95%CI 1.233-1.347,p<0.001)显著相关。
  • MetS2同样与全因死亡(HR 1.175,95%CI 1.088-1.269,p<0.001)和心血管疾病死亡(SHR 1.283,95%CI 1.245-1.323,p<0.001)显著相关。

核心结论

  • 将NAFLD纳入代谢综合征定义可识别更大比例具有代谢风险的人群,有助于早期干预并可能减轻全球医疗系统负担。

研究设计与样本

  • 研究分析1999至2018年NHANES收集的数据,共纳入46184名个体。
  • 比较美国心脏协会/国家心肺血液研究所(AHA/NHLBI)代谢综合征定义(MetS)与研究提出的纳入NAFLD的诊断标准(MetS2)两组间的临床特征和结局。
  • 采用多变量分析评估两组结局,并对通过粗化精确匹配(Coarsened Exact Matching)匹配的个体进行进一步亚组分析。

主要发现

  • 在46184名个体中,32.54%符合MetS标准,40.54%符合MetS2标准。
  • 在代谢综合征定义中考虑NAFLD后,额外纳入8.00%(n=3694)个体。
  • MetS与全因死亡(HR 1.184,95%CI 1.110-1.263,p<0.001)、心血管疾病死亡(SHR 1.288,95%CI 1.233-1.347,p<0.001)及主要不良心血管事件(MACE)显著相关。
  • MetS2同样与全因死亡(HR 1.175,95%CI 1.088-1.269,p<0.001)、心血管疾病死亡(SHR 1.283,95%CI 1.245-1.323,p<0.001)及MACE相关。

关键数值与推荐

  • MetS诊断采用美国心脏协会/国家心肺血液研究所(AHA/NHLBI)标准,MetS2为研究提出的纳入NAFLD的诊断标准。
  • 符合MetS标准者占32.54%,符合MetS2标准者占40.54%,MetS2额外识别8.00%(n=3694)个体。
  • MetS与全因死亡关联:HR 1.184(95%CI 1.110-1.263,p<0.001);与心血管疾病死亡关联:SHR 1.288(95%CI 1.233-1.347,p<0.001)。
  • MetS2与全因死亡关联:HR 1.175(95%CI 1.088-1.269,p<0.001);与心血管疾病死亡关联:SHR 1.283(95%CI 1.245-1.323,p<0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Metabolic syndrome (MetS) affects over one third of the US adult population. Despite its close association with non-alcoholic fatty liver disease (NAFLD), the traditional definition of MetS does not account for the presence of NAFLD. The present study thus aims to evaluate the inclusion of NAFLD in the diagnostic criteria of metabolic syndrome on its accuracy of capturing individuals with metabolic dysregulation and its prediction of adverse events. METHODS: Data collected from NHANES between 1999 and 2018 was analysed. Clinical characteristics and outcomes between individuals with metabolic syndrome from both the American Heart Association/National Heart, Lung, and Blood Institute (MetS) and the study's proposed diagnostic criteria (MetS2) were evaluated. Outcomes in both groups were evaluated with multivariate analyses, and further subgroup analysis on individuals matched with Coarsened Exact Matching was performed. RESULTS: Of 46,184 individuals included, 32.54% and 40.54% fulfilled MetS and MetS2 criteria respectively. Considering NAFLD in the definition of metabolic syndrome, a further 8.00% (n = 3694) were included. MetS was significantly associated with all-cause (HR: 1.184, 95% CI: 1.110-1.263, p < 0.001) and cardiovascular disease (CVD) mortality (SHR: 1.288, 95% CI: 1.233-1.347, p < 0.001), and major adverse cardiovascular events (MACE). MetS2 was similarly associated with all-cause (HR: 1.175, 95% CI: 1.088-1.269, p < 0.001), CVD mortality (SHR: 1.283, 95% CI: 1.245-1.323, p < 0.001) and MACE. CONCLUSION: Inclusion of NAFLD allows for identification a greater proportion of the population with metabolic risk. This allows for early intervention and potential to lift some burden off the global healthcare system.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fu CE, Yong JN, Ng CH, et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment Pharmacol Ther. 2023. PMID: 36710531. doi:10.1111/apt.17397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。